Filtered By:
Condition: Thrombosis
Procedure: Angioplasty
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 986 results found since Jan 2013.
Therapeutic effect of antithrombotic drug combinations in patients with atrial fibrillation undergoing percutaneous coronary intervention for coronary heart disease: a meta-analysis
CONCLUSIONS: DAT with NOACs has a higher safety profile against bleeding in patients with atrial fibrillation after PCI. DAT with VKAs was similar to TAT in terms of antithrombotic effect and incidence of bleeding.PMID:36628223 | PMC:PMC9827321
Source: American Journal of Translational Research - January 11, 2023 Category: Research Authors: Huabin He Xifeng Xiao Xiangyang Yuan Jianhai Chen Source Type: research
Bleeding Issues During Thrombolysis for Acute Leg Ischaemia
When we started testing catheter directed low dose thrombolysis (CDT) for acute leg ischaemia (ALI) in the 1980s, it was the first time endovascular intervention advanced beyond simple balloon angioplasty. In many respects, CDT kick started the endovascular revolution. Clots could be removed without surgery, and from arteries too small for embolectomy catheters to reach. But there was a price to pay: thrombolytic drugs caused bleeding, mainly from catheter puncture sites, but also from distant areas, such as haemorrhagic stroke.
Source: European Journal of Vascular and Endovascular Surgery - January 6, 2023 Category: Surgery Authors: Jonothan Earnshaw Tags: Invited Commentary Source Type: research
Very Short Versus Longer Dual Antiplatelet Treatment After Coronary Interventions: A Systematic Review and Meta-analysis
ConclusionsVSDAPT significantly decreased the odds of NACEs and major bleeding by 17% and 29%, respectively, without increasing ischemic events. Thus, VSDAPT could be well tolerated and feasible after PCI with DES.Clinical Trials RegistrationOpen Science Framework (10.17605/OSF.IO/4H2JB)Graphical AbstractVery short-term DAPT significantly reduces NACE and major bleedings, without affecting mortality and ischemic events (MACE, MI, stroke, stent thrombosis and revascularization).CI confidence intervals,DAPT dual antiplatelet therapy,DES drug-eluting stents,MACE major adverse cardiovascular events,MI myocardial infarction,NAC...
Source: American Journal of Cardiovascular Drugs - December 20, 2022 Category: Cardiology Source Type: research
Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis
ConclusionLong-term ticagrelor monotherapy after a short course of DAPT use showed better results in patients with T2DM following PCI. Therefore, ticagrelor monotherapy after a short course of DAPT use could be considered an evolution in antiplatelet therapy of this decade for the treatment of patients with T2DM after PCI. However, newer studies with a larger population size and cost-effectiveness are factors that should further be considered.
Source: Diabetes Therapy - December 9, 2022 Category: Endocrinology Source Type: research
A 28-year-old male with spontaneous coronary artery dissection complicated by apical thrombus and acute ischemic stroke: An interesting case
Radiol Case Rep. 2022 Nov 2;18(1):246-249. doi: 10.1016/j.radcr.2022.10.001. eCollection 2023 Jan.ABSTRACTSpontaneous coronary artery dissection is described as the intramural bleeding that separates the layers of an epicardial coronary artery wall, either with or without an intimal tear. Atherosclerosis, iatrogenic damage, or trauma are not linked to this syndrome. Here we present a 28-year-old male with 1 month history stroke but no any chronic disease as well family history of heart disease who presented with 2 days' duration of typical cardiac chest pain. Based on an emergency electrocardiogram that showed biphasic T-w...
Source: Atherosclerosis - November 10, 2022 Category: Cardiology Authors: Said Abdirahman Ahmed Mesut Karata ş L ütfi Öcal Mohamed Abdullahi Mohamud Ishak Ahmed Abdi Mohamed Omar Hassan Source Type: research
Aspirin vs. Clopidogrel for Chronic Maintenance Monotherapy after Percutaneous Coronary Intervention: the HOST-EXAM Extended Study
Conclusions: During an extended follow-up of over 5 years after randomization, clopidogrel monotherapy as compared with aspirin monotherapy was associated with lower rates of the composite net clinical outcome in patients without clinical events for 12±6 months after PCI with DES.PMID:36342475 | DOI:10.1161/CIRCULATIONAHA.122.062770
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Jeehoon Kang Kyung Woo Park Huijin Lee Doyeon Hwang Han-Mo Yang Seung-Woon Rha Jang-Whan Bae Nam Ho Lee Seung Ho Hur Jung-Kyu Han Eun-Seok Shin Bon-Kwon Koo Hyo-Soo Kim Source Type: research
Indobufen or Aspirin on Top of Clopidogrel after Coronary Drug-eluting Stent Implantation (OPTION): a Randomized, Open-label, Endpoint-blinded, Non-inferiority Trial
Conclusions: In Chinese patients with negative cardiac troponin undergoing DES implantation, indobufen plus clopidogrel DAPT compared with aspirin plus clopidogrel DAPT significantly reduced the risk of 1-year net clinical outcomes, which was mainly driven by a reduction in bleeding events without an increase in ischemic events.PMID:36335890 | DOI:10.1161/CIRCULATIONAHA.122.062762
Source: Circulation - November 6, 2022 Category: Cardiology Authors: Hongyi Wu Lili Xu Xin Zhao Huanyi Zhang Kang Cheng Xiaoyan Wang Manhua Chen Guangping Li Jiangnan Huang Jun Lan Guanghe Wei Chi Zhang Yinman Wang Juying Qian Junbo Ge Source Type: research
Endovascular treatment in patients with middle cerebral artery occlusion of different aetiologies
ConclusionsPatients with acute MCA M1 occlusion stroke due to different pathogeneses had comparable successful recanalization rates and functional independence at 90 days. The optimal management for MCAO patients with different aetiologies requires further research.
Source: Neuroradiology - November 5, 2022 Category: Radiology Source Type: research
Efficacy and Safety of Shortened Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials
In conclusion, this study showed that ≤3-month DAPT may be a valid option for most patients after percutaneous coronary intervention. Because reductions in major adverse cardiovascular event, all-cause mortality, and cardiovascular mortality were not seen in patients with HBR, this also highlights the need for specific studies in these patients about optimal duration of antiplatelet therapy.
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Original Article Source Type: research
